Non-erosive reflux disease (NERD) and erosive esophagitis - A spectrum of disease or special entities?;Nicht-erosive refluxerkrankung (Non-erosive Reflux Disease, NERD) und erosive ösophagitis - Ein krankheitsspektrum oder verschiedene erscheinungsbilder derselben krankheit?

Zeitschrift fur Gastroenterologie

Volumn 45, Issue 11, 2007, Pages 1156-1163

  Fass, Ronnie ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

GERD; NERD; Reflux esophagititis

Indexed keywords

CONCEPTUAL FRAMEWORK; DISEASE COURSE; DISEASE DURATION; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEREDITY; NON EROSIVE REFLUX DISEASE; PHENOTYPE; REFLUX ESOPHAGITIS; REVIEW; STOMACH FUNCTION DISORDER;

ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GERMANY; HUMANS; TERMINOLOGY AS TOPIC;

EID: 37349047176     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963628     Document Type: Review

References (52)

1. Fass R, Ofman J. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-1909
2. Fass R. Gastroesophageal reflux disease revisited. Gastroenterol Clin North Am 2002; 31: S1-S10
3. Fass R. Distinct phenotypic presentations of gastroesophageal reflux disease: a new view of the natural history. Dig Dis 2004; 22: 100-107
4. Pace F, Bianchi Porro G. Gastroesophageal reflux disease: A typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004; 99: 946-949
5. Quigley E. Non-erosive reflux disease: a part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13 (Suppl 1): S13-18
6. Agrawal A, Castell D. GERD is chronic but not progressive (editorial). J Clin Gastroenterol 2006; 40: 374-375
7. Spechler S, Goyal R. Barrett's esophagus. N Engl J Med 1986; 315: 362-371
8. Labenz J, Jaspersen D, Kulig M et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004; 99: 1652-1656
9. Fass R, Fennerty M, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-314
10. Chiba N, De Gara C, Wilkinson J et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 117: 1798-1810
11. Richter J, Peura D, Benjamin S et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810-1816
12. Kaltenbach T, Crockett S, Gerson L. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965-971
13. Hanno S, Rastogi A, Weston A et al. Detection of Barrett's esophagus after endoscopic healing of rrosive esophagitis. Am J Gastroenterol 2006; 101: 1416-1420
14. Pace F, Bollani S, Molteni P et al. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis 2004; 36: 111-115
15. Pace F, Pallotta S, Molteni P et al. Natural history of NERD in 3 Italian tertiary referral centres after 5 years of follow-up. Gut 2006; 55 (Suppl 5): A62
16. Shapiro M, Green C, Faybush E et al. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther 2006; 23: 321-329
17. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): Comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41: 131-137
18. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991; 32: 845-848
19. Kuster E, Ros E, Toledo-Pimentel V et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994; 35: 8-14
20. Isolauri J, Luostarinen M, Isolauri E et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41
21. McDougall N, Johnston B, Kee F et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-486
22. McDougall N, Johnston B, Collins J et al. Disease progression in gastrooesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastro-enterol Hepatol 1997; 9: 1161-1167
23. Manabe N, Yoshihara M, Sasaki A et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002; 17: 949-954
24. Labenz J, Nocon M, Lind T et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol 2006; 101: 2457-2462
25. Willich S, Nocon M, Kulig M et al. Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 2006; 23: 371-376
26. Garrido Serrano A, Guerrero Igea F, Lepe Jiménez J et al. Clinical features and endoscopic progression of gastroesophageal reflux disease. Rev Esp Enferm Dig (Madrid) 2003; 95: 712-716
27. Sontag S, Sonnenberg A, Schnell T et al. The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol 2006; 40: 398-404
28. Bardhan K, Royston C, Nayyar A. Reflux rising! An essay on witnessing a disease in evolution. Dig Liver Dis 2006; 38: 163-168
29. Fass R, Sampliner R. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003; 63: 555-564
30. Sampliner R, Fennerty M, Garewal H. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44: 532-535
31. Goldman M, Beckman R. Barrett syndrome. Case report with discussion about concepts of pathogenesis. Gastroenterology 1996; 39: 104-110
32. Endo M, Kobayashi S, Kozu T et al. A case of Barrett's epithelialisation followed up for 5 years. Endoscopy 1974; 6: 48-51
33. Halvorsen J, Semb B. The "Barrett syndrome" (the columnar-lined lower esophagus): An acquired condition secondary to reflux esophagitis. Acta Chir Scand 1975; 141: 683-687
34. Cameron A, Arora A. Barrett's esophagus and reflux esophagitis: is there a missing link? Am J Gastroenterol 2002; 97: 273-278
35. Cameron A, Lomboy C. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-1245
36. Fitzgerald R, Onwuegbusi B, Bajaj-Elliott M et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002; 50: 451-459
37. Fitzgerald R, Farthing M. The pathogenesis of Barrett's esophagus: A process in continuum or discontinuum. Curr Gastroenterol Rep 2000; 2: 421-424
38. Stoltey J, Reeba H, Ullah P et al. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2007; 25: 83-91
39. Cameron A, Lagergren J, Henriksson C et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002; 122: 55-59
40. Romero Y, Cameron A, Locke G et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113: 1449-1456
41. Quigley E. Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S24-30
42. Castell D, Kahrilas P, Richter J et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-583
43. Hetzel D, Dent J, Reed W et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-912
44. Sifrim D, Holloway R, Silny J et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001; 120: 1588-1598
45. Fass R, Naliboff B, Higa L et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1988; 115: 1363-1373
46. Vela M, Camacho-Lobato L, Srinivasan R et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeptazole. Gastroenterology 2001; 120: 1599-606
47. Wiklund I, Bardhan K, Muller-Lissner S et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998; 30: 19-27
48. Stalhammer N, Carlsson J, Peacock R et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999; 16: 483-497
49. Gerson L, Robbins A, Garbert A et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Gastroenterology 2000; 95: 395-407
50. Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-979
51. Jones R, Hungin A, Phillips J et al. Gastroesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings. Eur J Gen Pract 1995; 1: 149-154
52. Dean B, Gano Jr A, Knight K et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-664